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ABSTRACT 
INTRODUCTION 
                    Diabetes mellitus is a metabolic disorder characterized by 
hyperglycemia and insufficiency of secretion or action of endogenous insulin.  
                     Currently the number of cases of diabetes worldwide is estimated to 
be around 150 million. India leads then world with the largest number of diabetic 
subjects earning the dubious distinction of being the “diabetic capital of the 
world”.  
                   Obesity has induced many public health problems related to 
metabolic diseases, including glucose intolerance, hypertension, 
hyperinsulinemia, dyslipidemia and atherosclerosis. Moreover these complexes 
are known to increase the risk of cardiovascular diseases. In  particular , the 
accumulation of adipose tissue predominantly  in visceral cavity plays a major 
role in development of metabolic syndrome and cardiovascular disease. 
                Therefore estimating the visceral fat accumulation is important in terms 
of evaluating the patients with high risk of cardiovascular disease.   Generally 
computerized tomography (CT) is recognized as the standard method of 
estimating the visceral fat. But, exposure to radiation, high cost of CT, low 
availability prevents the wide use of CT, in clinical and epidemiological studies.  
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              Therefore alternative methods which are simple and non invasive have 
been used in assessing the visceral fat thickness. Some of the alternative methods 
are, Body mass Index, waist hip ratio, dual energy X-ray absorptiometry and 
ultrasonography.  
               Ultrasonography is a reliable and convenient method of quantifying the 
amount of visceral fat and the diverse USG values have been reported to be useful. 
AIMS AND OBJECTIVES  
1) To assess the independent relationship between visceral fat thickness and 
cardiovascular risk in type 2 diabetes patients. 
2) To assess whether the above parameters helps to identify the high risk group 
for cardiovascular diseases.  
MATERIALS AND METHODS 
PLACE OF THE STUDY  
                  The study was conducted at Government Rajaji Hospital, Madurai 
Medical college, Madurai. 
STUDY DESIGN 
                  Observational type of study 
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STUDY POPULATION 
               50 patients who are known case of type 2 diabetes mellitus were selected 
from Department of Diabetology , Government Rajaji Hospital , Madurai  
METHODOLOGY  
          50 patients who are known case of type 2 diabetes mellitus were analysed for 
this study.   A thorough clinical evaluation was made and detailed history, blood 
pressure, height, weight, waist and hip circumference  were taken .  
a) Fasting lipid profile was done by enzymatic methods like zaks method, and 
spot urine sample for microalbuminuria were taken. 
b) Visceral fat thickness was measured in fasting and in full expiration. The 
distance between the internal surface of rectus abdominis muscle and the 
posterior wall of aorta is measured.  
RESULTS 
- Out of the 50 subjects, the visceral fat thickness was measured and patient 
were categorized into VFT < 5.5, 5.6 – 6.5 , 6.6 – 7.5 and > 7.5. The mean 
visceral fat was 6.08 among the 50 subjects.  
- Among the 50 diabetic subjects (25 males and 25 females) attending the 
department of Diabetology in Government Rajaji Hospital, Madurai, with  
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BMI of > 25, increased visceral fat thickness was found in 12 males and 15 
females.  
- Among the 50 patients, all the patients who had increased visceral fat 
thickness had an increased triglyceride level and increased LDL level. 
Therefore there is a strong positive correlation between increased visceral fat 
thickness and LDL, TGL levels. 
- Similarly , 13 patients had microalbuminuria, out of which more than 90% 
of patients had a Visceral fat thickness of more than 7.5 . They also had a 
increased triglyceride level and LDL levels.  
- There was no significant correlation between visceral fat thickness and total 
cholesterol levels. Similarly even HDL  didn’t show show any strong 
correlation with visceral fat thickness levels.  
CONCLUSION 
  Eventhough there are many parameters to assess the cardiovascular risk like BMI, 
WHR, etc, measuring  the visceral fat thickness is a reliable indicator to assess the 
cardiovascular risk.  
                       This study which was conducted in Government Rajaji Hospital 
among 50 type 2 diabetic subjects, showed a strong positive correlation between 
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visceral fat thickness with LDL and triglycerides levels. Similarly 13 patients had 
microalbuminuria whose visceral fat thickness was > 7.5.  
                     Because of presence of microalbuminuia, there is evidence of 
subclinical endothelial injury in this patients who are more prone for 
cardiovascular risk in later part of their life. These patients also had a elevated 
LDL and TGL which supports the point on cardiovascular risk.  
                         Eventhough CT was considered to be gold standard in measuring 
the visceral fat thickness, there are many studies which showed ultrasonographic 
measurement of visceral fat was equally efficient in assessing the cardiovascular 
risk. Moreover due to radiation exposure and cost of CT, this study was conducted 
with  ultrsonographic measurement alone.  
Therefore, it is concluded that , visceral adiposity has a strong positive correlation 
with lipid profile and microalbuminuria, by which it is easy to predict the diabetics 
who are more prone for cardiovascular risk .  
KEY WORDS : diabetes mellitus, visceral fat thickness, microalbuminuria, BMI, 
triglycerides and LDL.  
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INTRODUCTION 
                    Diabetes mellitus is  a metabolic disorder characterized by 
hyperglycemia and insufficiency of secretion or action of endogenous insulin.  
                     Currently the number of cases of diabetes worldwide is estimated to 
be around 150 million. India leads then world with the largest number of diabetic 
subjects earning the dubious distinction of being the “diabetic capital of the 
world”. The international diabetes Federation estimates the total number of 
diabetic subjects to be around 40.9 million in India and this is further to be set to 
rise to 69.9 million by the year 2025. 
                   Obesity has induced many public health problems related to 
metabolic diseases, including glucose intolerance, hypertension, 
hyperinsulinemia, dyslipidemia and atherosclerosis. Moreover these complexes 
are known to increase the risk of cardiovascular diseases. In  particular , the 
accumulation of adipose tissue predominantly  in visceral cavity plays a major 
role in development of metabolic syndrome and cardiovascular disease. 
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                     Therefore estimating the visceral fat accumulation is important in 
terms of evaluating the patients with high risk of cardiovascular disease.  
              Generally computerized tomography (CT) is recognized as the standard 
method of estimating the visceral fat. But, exposure to radiation, high cost of CT, 
low availability prevents the wide use of CT , in clinical and epidemiological 
studies.  
              Therefore alternative methods which are simple and non invasive  have 
been used in assessing the visceral fat thickness. Some of the alternative methods 
are, Body mass Index , waist hip ratio, dual energy X-ray absorptiometry and 
ultrasonography.  
               Ultrasonography is a reliable and convenient method of quantifying the 
amount of visceral fat and the diverse USG values have been reported to be 
useful. 
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AIMS AND OBJECTIVES 
 
1) TO ASSESS THE INDEPENDENT RELATIONSHIP BETWEEN 
VISCERAL FAT THICKNESS AND CARDIOVASCULAR RISK IN 
TYPE 2 DIABETES PATIENTS. 
2) TO  ASSESS WHETHER THE ABOVE PARAMETERS HELPS TO 
IDENTIFY THE HIGH RISK GROUP FOR CARDIOVASCULAR 
DISEASES.  
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REVIEW OF LITERATURE 
Diabetes mellitus (DM) refers to a group of common metabolic disorders 
that share the phenotype of hyperglycemia . Several distinct types of Diabetes 
mellitus exist and are caused by a complex interaction of genetics and 
environmental factors. Depending on the etiology of DM, factors contributing to 
hyperglycemia include reduced insulin secretion , decreased glucose utilization 
and increased glucose production. 
 
CLASSIFICATION OF DIABETES 
1) Type I diabetes (beta cell destruction,  leading to absolute insulin 
deficiency) 
a) Immune mediated 
b) Idiopathic 
2) Type 2 diabetes (range from predominantly insulin resistance with relative 
insulin deficiency to a predominantly insulin secretory defect with insulin 
resistance) 
3) Other specific types types of diabetes 
a) Genetic defects of beta cell function characterized by mutations in  
- Hepatocyte nuclear transcription factor(HNF) 4 alpha (MODY 1) 
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- Glucokinase (MODY 2)  
- HNF 1 alpha  
- Insulin promoter factor 1(MODY 4) 
- HNF 1 beta (MODY 5) 
- Neuro D1 (MODY 6) 
- Mitochondrial DNA 
- Subunits of ATP sensitive potassium channels 
- Proinsulin or insulin conversion 
b) Genetic defects in insulin action 
- Type  A insulin resistance 
- Leprachaunism 
- Rabson –Mendenhall syndrome 
- Lipodystrophy syndromes 
c) Diseases of exocrine pancreas  - pancreatitis , pancreatectomy , 
neoplasia, cystic fibrosis, hemochromatosis, fibrocalculous 
pancreatopathy.  
d) Endocrinopathies- acromegaly, cushings dyndrome, glucaganoma, 
pheochromocytoma, hyperthyroidism, somatostatinoma, 
aldosteronoma.  
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e) Drug or chemical induced – glucocorticoids, pentamidine, nicotinic 
acid, diazoxide, adrenergic agonists, thiazides, hydantoins.      
f) Uncommon forms of immune medicated diabetes – “stiff person” 
syndrome,  anti insulin receptor antibodies. 
g) Other genetic syndromes sometimes associated with diabetes – Downs 
syndrome, Klinefelters syndrome, Turners syndrome, Wolframs syndrome, 
Friedreich’s ataxia, Huntington’s chorea, Laurence Moon- Biedl syndrome 
, myotonic dystrophy ,  porphyria,  Prader Willi syndrome. 
h) Infections – congenital rubella , CMV, coxsackie 
i) Gestational diabetes mellitus. 
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CRITERIA FOR DIAGNOSIS OF DIABETES MELLITUS 
 
 
1. Symptoms of diabetes plus casual plasma glucose concentration  - 200 mg/dl 
(11.1 mmol/L) 
l). Casual is defined as any time of day without regard to time since last meal. 
The classic symptoms of diabetes include polyuria, polydipsia, and unexplained 
weight loss. 
                                                             OR 
2.  FPG > 126 mg/dl (7.0 mmol/l).  
     Fasting is defined as no caloric intake for at least 8 h. 
                                                            OR 
    A1C > 6.5%. 
                                                           OR 
3. 2-hr postload glucose > 200 mg/dl (11.1 mmol/l) during an OGTT. The test 
should be performed as described by WHO, using a glucose load containing the 
equivalent of 75 g  anhydrous glucose dissolved in water. 
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RISK FACTORS FOR  TYPE 2 DIABETES MELLITUS 
 
1) Family history of diabetes ( i.e., parent or sibling with type 2 diabettes) 
2) Obesity (BMI > 25kg/m2 ) 
3) Habitual physical inactivity 
4) Race / ethnicity ( eg : African American, Latino , Native American , Asian 
American, Pacific Islander)  
5) Previously identified IFG or IGT or and A1c of 5.7 – 6.4 % 
6) History of GDM or delivery of a baby of >4 kg  
7) HDL cholesterol < 35 mg/dL(0.90mmol/L) and/or a triglyceride 
>250mg/Dl (2.82mmol/L) 
8) Polycystic ovarian syndrome or acanthosis nigricans 
9) History of vascular disease. 
 
MODE OF PRESENTATION OF DIABETES MELLITUS 
Diabetes can be detected in one of the following ways : 
Some patients are found to have excess of glucose or sugar in urine incidentally 
on routine check up without any complaints or physical signs. 
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Some patients are found to have diabetes while investigating for an associated 
complaint like, ischemic heart disease, hypertension, eye diseases, kidney disease 
, non healing foot ulcers etc.. 
Diabetes can manifest as an acute illness  - ketoacidosis with an acute infection 
or even without evidence of any cause. Pain abdomen and vomiting may be the 
presenting complaints in some patients. This most commonly occurs in juvenile 
onset diabetes mellitus (IDDM) 
Some  of the patients often present with classical symptoms of diabetes. E.g. , 
excessive thirst,  frequent micturition , increased appetite , weight loss, severe 
weakness, repeated infections, intching in genitals, diminished vision, numbness 
in limbs and occasionally impotence 
COMPLICATIONS OF DIABETES MELLITUS 
ACUTE METABOLIC COMPLICATIONS 
The two main metabolic complications of diabetes are diabetic ketoacidosis and 
hyperosmolar state. Initially DKA was considered as the hallmark of Type I DM, 
but it also in individuals who lack immunologic features of type 1 Diabetes, who 
can subsequently treated with oral glucose lowering agents. Hyperosmolar state 
is most frequently seen in type 2 diabetes. Both are anyway associated with 
relative insulin insulin deficiency, volume depletion and acid base abnormalities.  
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CHRONIC COMPLICATIONS OF DIABETES 
1) Microvascular  
a) Eye disease  -  retinopathy (proliferative and non proliferative) 
                                       Macular edema 
b) Neuropathy  - sensory and motor (mono and polyneuropathy) 
                        Autonomic 
c) Nephropathy  
2) Macrovascular  
a) Coronary artery disease 
b) Peripheral arterial disease  
c) Cerebrovascular disease 
3) Others  
a) Gastrointestinal (gastroparesis, diarrhea) 
b) Genitor urinary (uropathy / sexual dysfunction) 
c) Infections 
d) Dermatological 
e) Glaucoma 
f) Cataracts 
g) Periodontal diseases 
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h) Hearing loss. 
DIABETIC RETINOPATHY 
Diabetic retinopathy is classified into proliferative diabetic retinopathy (PDR) 
and non proliferative diabetic retinopathy(NPDR).  Hemorrhages or 
microaneurysms, cotton wool spots , hard exudates , intra retinal microvascular 
abnormalities , venous caliber abnormalities like venous loops, venous bleeding 
and venous tortuosity are some of the findings associated with early and 
progressive diabetic retinopathy. Micro aneurysms and saccular outpouchings of 
the capillary walls that can leak fluid  and   results in intra retinal edema and 
hemorrhages. These intra retinal hemorrhages are flame shaped or dot blot  like 
appearance , reflecting the architecture of the layer of the retina in which they 
occur. Flame shaped hemorrhages occur in inner retina closer to the vitreous and 
dot blot hemorrhages occur deep in the retina. Intra retinal microvascular 
abnormalities are either new vessel growth within retinal tissue or shunt vessels 
through areas of poor vascular perfusion. 
                  The micro infarcts in the nerve fibre layer of retina are called cotton 
wool spots. Retinal detachment can occur due to neovascularisation with fibrous 
tissue contraction that can distort retina and lead to traction.  
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               However the most common cause of blindness in diabetes is macular 
edema. Especially macular edema involving the fovea or non perfusion of the 
capillaries in the central macula is responsible for loss of vision. Macular edema  
more likely to occur in patients withT2DM which represents 90% to 95% of 
diabetic population. 
DIABETIC NEUROPATHY 
               Diabetic neuropathy has a number of clinical syndromes with 
subclinical or clinical manifestations depending upon the class of nerve fibres 
involved , it can manifest as polyneuropathy,  mononeuropathy or autonomic 
neuropathy.  
Distal symmetrical polyneuropathy is the most common form of diabetic 
neuropathy, where patients frequently present with distal sensory loss. 
Hyperesthesia, paresthesia and dysesthesia can also occur. Symptoms may 
include a sensation of numbness , tingling, sharpness, that begins in feet and 
spreads proximally. As diabetes progresses , the pain subsides and eventually 
disappears , but a sensory deficit in lower limbs persists. 
   Diabetic polyradiculopathy is a syndrome characterized by severe disabling 
pain in the distribution of one or more nerve roots, which can be accompanied by 
motor weakness. There can be severe pain in hip and thigh due to involvement of 
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lumbar plexus   . Fortunately   this condition is usually self limited and resolves 
in 6 – 12 months .  
 
Mononeuropathy is less common than polyneuropathy in diabetes which presents 
with pain and motor weakness in distribution of single nerve. Third cranial nerve 
is more commonly involved and heralded by diplopia. Sometimes 4 th , 6th and 7th 
cranial nerves are also involved. Peripheral mononeuropathies  can also occur. 
              Autonomic neuropathy in diabetes can involve multiple systems like 
cardiovascular, gastrointestinal, genito urinary etc. Patient can have resting 
tachycardia and orthostatic hypotension when cardiovascular system is involved. 
Gastropathy and bladder dysfunction are caused by autonomic neuropathy of 
gastrointestinal tract and genito urinary tract.  
Hyperhidrosis of upper extremities and anhidrosis of lower extremities can occur 
due to sympathetic nervous system dysfunction. There is a increased chance of 
foot ulcers due to anhidrosis of lower extremities which causes dry skin and 
cracking.  
Autonomic neuropathy may reduce the counter regulatory hormone release 
leading to an inability to sense hypoglycemia appropriately (hypoglycemia 
unawareness) thereby subjecting the patient to the risk of severe hypoglycemia . 
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DIABETIC NEPHROPATHY 
It is characterized clinically by hypertension, proteinuria and ultimately renal 
impairment. Diabetic neuropathy has 5 stages , out of which stage 1, 2 and 3 are 
considered as pre clinical or “silent” and stages 4 and 5 are called as clinical 
diabetic neuropathy .  
Stage 1 
  Here GFR  is elevated on an average by 20 – 40% above that of age matched 
normal controls in both adults and children with type 1 DM resulting in 
glomerular enlargement 
Stage 2 
   It is an extension of stage 1. Histopathological changes like basal membrane 
thickness and messangial expression begins to be detected within 1 st two years 
after onset of IDDM. This stage is usually silent clinically with normal albumin 
excretion rate despite structural changes. Most patients remain in stage 2 , 
however 30 % - 40% progress to subsequent stages. 
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Stage 3  
   Here patients will have microalbuminuria detected. Patients who have albumin 
excretion  rates > 30µg /min are more likely  to develop clinical diabetic 
nephropathy than those with less than 30 µg/min. 
Stage 4  
    In this stage, patients develop overt nephropathy. By definition , patients have 
persistant clinical proteinuria with albumin exretion rate of > 250µg/min in 24 
hours, hypertension and a decrease in GFR. Once proteinuria is persistently 
present, development of end stage renal disease or death occurs in 3 – 4.8 years. 
Stage 5  
      This is a stage of advanced renal failure. In contrast to non diabetic patients, 
diabetics with end stage renal disease usually have other systemic manifestations 
in addition to their renal diseases. 
PATHOGENESIS OF TYPE 2  DIABETES  MELLITUS. 
           The earliest abnormality seen   in type 2 diabetes in impairment in tissue 
sensitivity to insulin. This results in an increase in demand on the β cell to 
maintain a sufficiently high rate of insulin secretion to the offset of insulin 
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resistance. After a certain time, when the insulin secretion fails to meet the 
insulin demand , overt diabetes occurs. 
Defective first phase insulin secretion : 
   This phase of insulin secretion , helps in priming the insulin target tissues to 
maintain the normal glucose homeostasis. It is one of the early manifestation, 
which is found to occur when fasting glucose rise to 115 – 120 mg% 
Defective pulsatile insulin secretion: 
Insulin is normally secreted in pulses of rapid frequency. Abnormal oscillatory 
insulin secretion is a feature of early stage of type 2 diabetes.  
Genetic factors affecting βcell function : 
- Glucose transporter  2 defect 
- Decreased glucokinase activity 
- Defects in phosphoinositol 
- Defects in intracellular calcium and potassium metabolism 
Environmental factors affecting βcell function: 
- Chemical toxins  like alcohol 
- Malnutrition 
- Chronic pancreatitis 
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- Amylin accumulation 
- Intrauterine environment 
- Drugs like thiazides, beta blockers etc.., 
Effects of chronic hyperglycemia : 
       Two different entities have been recognized. 
a) Glucose desensitization : 
- Temporary reversible state of cellular refractoriness which occur as 
an impaired insulin exocytotic mechanism. 
b) Glucose toxicity : 
- Irreversible alteration of cellular  function occur as a result of 
impairment in the regulatory process responsible for normal insulin 
gene transcription.  
 
 ROLE OF LIVER IN GLUCOSE METABOLISM 
1)  Liver is the organ of glucose production and glucose consumption 
2) It is exposed to insulin concentration in the portal circulation which is 3 – 
10 times more the systemic circulation. 
3) Sole site of glycol regulatory action of glucose. 
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4) Absorbed hexose’s reach liver before reaching muscle and adipose tissues. 
Liver has storage form of glucose and glycogen about 70 gm at a time. 75% of 
hepatic glucose output comes from glycogenolysis. Remaining 25% of hepatic 
glucose output comes from gluconeogenesis. 
Contribution of liver in glucose homeostasis depends on the following factors : 
1) Sensitivity of  hepatocytes to small increments in insulin levels 
2) Ratio of insulin to glucagon 
3) Responsiveness of glycogenolysis and gluconeogenesis to hormonal 
modulation.  
HYPERINSULINEMIA  AND  INSULIN RESISTANCE 
It is observed that population with type 2 diabetes have hyperinsulinemia and this 
reflects compensatory β cell response to the underlying insulin resistance. In 
Pima  Indians , primary hypersecretion of insulin by β cells may represent the 
basic genetic defect. 
Insulin secretion : 
Much confusion is caused by discussion of inadequate secretion , yet there is a 
talk about  hyperinsulinemia in type 2 diabetes. Hyperinsulinemia is a 
compensatory attempt to deal with chronic hyperglycemia. The β cells are 
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defective in that, they are unable to respond to any further increased by in plasma 
concentration caused by eating. This is essential point response of the β cells to 
ingested substrates is subnormal.  
Histology of pancreas in type 2 diabetes has provided useful clues to the 
pathogenesis of poor insulin secretory response. Unlike in type 1 diabetes, is only 
moderately reduced in most cases. It is known that this results from chronic 
deposition of islet polypeptide which is co secreted with insulin. The amyloidal 
material is laid down in proximity to the β cell membrane and it interferes with 
the cell membrane based process of insulin resistance.  
DIABETES – OBESITY AND INSULIN RESISTANCE 
Insulin resistance and hyperinsulinemia is being increasingly implicated in the 
pathogenesis of various metabolic disturbances. Some of them has been clubbed 
under as a syndrome. 
Diagnosis of metabolic syndrome is made in presence of atleast 3 of the 
following. 
1) Waist circumference > 102 cm in male and > 88 cm in females 
2) Triglycerides > 150 mg/dl (or) patients using nicotinic acid or fibrates. 
3) HDL < 40 mg/dl in males and < 50 mg/dl in females 
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4) Systolic BP ≥ 130 mmHg (or) diastolic BP > 85 mmHg (or) patients using 
anti hypertensives  
5) Fasting blood sugar > 100mg/dl (or) patients using OHA’s. 
Although much work is being carried out to learn the cellular mechanisms which 
are associated with resistance to insulin action especially in liver , muscles and 
fat cells, several conditions has been associated with insulin resistance. Obesity is 
one of them. 
The combination of insulin resistance and hyperinsulinemia can lead to 
metabolic cascade which can lead to other disturbance like atherosclerosis , 
hypertension etc.. 
In patients who are prone to diabetes, the capacity of beta cells to increase the 
secretion of insulin is compromised  and  a stage is reached when beta cells are 
not able to augment insulin secretion , leading to glucose intolerance and 
diabetes. Many studies has analysed that BMI was associated with increased 
diabetes independently of fasting and postprandial   levels. The American study 
showed that BMI>35kg/m2  has  40 old increase in type 2 DM  as compared to 
BMI <23kg/m2.  
           Eventhough BMI was considered to be the tool for assessing 
cardiovascular risk in type 2 DM , there are certain limitations for using BMI for 
21 
 
diagnosing and assessing the cardiovascular risk in obese group, particularly in 
certain ethnic groups. 
         Two people with similar BMI and of same sex, height, age can have 
different phenotypes and   presentations   depending on    body   fat   distribution    
(central or peripheral). Therefore, visceral adiposity measurement is now a  days 
used to assess the cardiovascular risk in a patient with type 2 DM.  
VISCERAL OBESITY 
It has been now recognized that, insulin resistance is more likely related with the 
type of adiposity , which is greater with central obesity. Even some studies have 
proved that , there is a stronger correlation with intra abdominal visceral fat 
mass. Specific fat deposits like mesenteric fat and omental fat tissues are more 
important in this association. The visceral fat tissue is more closely associated 
with insulin resistance and cardiovascular risk when compared to the 
subcutaneous fat . 
Why visceral fat ? 
Visceral fat, especially mesenteric fat which is drained by portal circulation is 
metabolically more active than subcutaneous fat.  Visceral adipocytes are more 
sensitive to the lipolytic effects of catecholamines and anti lipolytic effects of 
insulin leading to increased free fatty acids production.  
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              This can lead to reduced fat oxidation and ectopic fat deposition which 
worsens the insulin resistance by reducing the peripheral glucose uptake. At the 
same time , visceral adipocytes are known to produce large number of cytokines 
like IL – 6, TNF α , angiotensin II, all of which can increase the cardiovascular 
risk in type 2 diabetes patients.  
Free fatty acids in obese patients : 
There is increase in the level and flux of free fatty acids in centrally obese 
patients. Insulin resistance can be associated with hyperinsulinemia in the 
presence of functioning beta cells. Insulin has a potent antilipolytic action. So, 
inspite of raised insulin, levels of FFAs should be increased.  The increased 
levels  of FFAs depend on the relative roles of lipolytic force against the 
antilipolytic force of insulin.  
               Adipose tissues at different sites has different metabolic properties.  
Similarly all the adipose cells do not respond to the stimuli in a same manner. 
Many authors have suggested that, people with visceral adiposity has a relative 
insulin resistance to the anti lipolytic effects of insulin. The reason behind this is, 
the adipose cells of  the visceral mass have  a relatively poor density of insulin 
receptors and therefore they are not  susceptible to the antilipolytic effects of 
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insulin. At the same time, they have high density of glucocorticoid receptors and 
can respond to the lipolytic action of each steroid hormone. 
How do fat cells affect insulin sensitivity? 
               The free fatty acids , interfere with the insulin action, glucose uptake 
and utilization in muscle through the glucose fatty acid hike. Even some studies 
have focused on the roll of free fatty acids on glucose receptors. Circulating free 
fatty acids has a role to play in translocation from their intracellular location to 
the cellular membrane.  
           Increased flux of free fatty acids will expose the liver to high levels of 
FFAs. In these circumstances, there is an increase in gluconeogenesis dependant 
on the levels of free fatty acid oxidation in liver.  Similarly excess FFAs can also 
lead to hepatic insulin resistance and can decrease the hepatic clearance of 
insulin.  Therefore visceral adiposity can explain the presence of both hepatic and 
peripheral insulin resistance which would be then refluxed by increased insulin 
secretion and hyperinsulinemia. At the same time , it would be naïve to suggest 
that elevated levels of FFAs would be the only cause of insulin resistance. 
Role of fat cells and inflammation in obesity :  
The human body has limited capacity to generate new fat cells. 
24 
 
 A 70 kg man is thought to have 35 – 50 billions fat cells which are distributed in 
subcutaneous tissues and abdominal cavity . Once the person becomes 
overweight with type 2 diabetes, the ingested excess energy will be stored as fat 
in the existing fat cells by becoming hypertrophic. 
                Once the fat cells exceeds their capacityto intake circulating lipids, 
they will be enhanced to secrete variety of inflammatory cytokines and 
consequently fat begins to deposit in extracellular tissues such as muscle,  liver , 
vascular walls and inflammatory viscious cycle begins. Hyperlipidemia and 
insulin resistance would further aggravate and development of atherosclerosis 
and other complications manifest. 
             Hypertrophied fat cells, particularly intra abdominal visceral fat produce 
increased amounts of cytokines that causes systemic inflammation. Moreover 
these cytokines that cause systemic inflammation, drain directly into the liver 
through portal circulation thus exposing the liver to high levels of inflammatory 
agents. 
These potent inflammatory signals, increases the hepatic production of CRP, 
interleukins, TNF α , which are common findings in obese individuals. Excess  
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fatty acids further aggravates insulin resistance and abnormalities in other tissues, 
including development of fatty streaks and formation of atheromatous plaques in 
arterial walls. 
Neuro endocrine aberrations : 
The raised levels of free fatty acids would be dependant on increased degree of 
lipolytic drive. It has been proved that, this lipolytic drive which is associated 
with  visceral adiposity is a complex hypothalamic driven endocrine aberration. 
The  components  of  which are  a) increase  in sympathetic nervous system 
activity      2) complex steroid hormone disturbance. 
a) Sympathetic  nervous system hyperactivity (SNS)  : 
                    It has been postulated that , the main lipolytic stimuli in 
visceral obesity may be the sympathetic nervous system hyperactivity. The 
increased lipolysis associated with visceral obesity may be an additional 
activity of SNS hyperactivity.  There are many works which have 
undergone in animals and humans, which showed that caloric intake 
increases and fasting decreases the activity of SNS. These changes are 
closely related to the levels of serum insulin. Some studies even showed 
that, higher the insulin levels, greater the activity of sympathetic nervous 
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system. Thus obesity associated with hyperinsulinemia and insulin 
resistance would again increase the activity of SNS. 
        In addition to the effects of catecholamines which has a prolipolytic 
action, it has been now recognized that, epinephrine is a very powerful 
insulin antagonist and it can inhibit insulin mediated glucose uptake by 
muscles and block the suppressive action of insulin in hepatic 
gluconeogenesis.  
b) Steroid hormone imbalance : 
                   In visceral obesity, there is a functional hyperactivity of the 
CRH – ACTH – cortical axis. Centrally, the hypothalamus plays a 
important role with increased sensitivity and preparedness of CRH – 
ACTH – axis to stimulate  such  a mental and physical stress. Peripherally 
there is an increased metabolic clearance of cortisol. The region where this 
take splace is the visceral fat depot as this is known to contain high density 
of glucocorticoid receptors and is well placed to respond to the raised 
cortisol levels as well as participate in increased clearance. 
          
 Raised androgen levels in women and hypogonadal levels in men with 
functional hypercortisolism which is seen in visceral obesity , amplify the 
degree of insulin resistance , either directly or through increase in free fatty 
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acid levels. Women with visceral obesity have hyperandogenesity , typical 
of women with polycystic ovarian disease. These women have 
hyperandrogen levels, central obesity , insulin resistance and 
hyperinsulinemia. The effect of androgens on lipid metabolism is that, they 
are known to increase the lipolytic sensitivity by expression of lipolytic 
beta-adrenergic receptors through an androgen receptor which in turn  
autoregulated by testosterone. 
                   Thus it has been known that neuro endocrine disturbances  can 
cause visceral obesity and insulin resistance and therefore hormonal 
imbalance has to be corrected as  a primary aim . Inspite of this, the two 
aberrations namely visceral obesity and neuroendocrine disturbance are so 
interrelated in their effects, it is possible that, both play an important  and 
symbiotic role leading to insulin resistance and hyperinsulinemia.  
 
DIABETIC DYSLIPIDEMIA 
Dyslipidemia is a common feature of both type 1 and type 2 diabetes. 
The common patterns of dyslipidemia in type 2 diabetes are : 
1) Elevated triglycerides levels 
2) Low plasma HDL cholesterol (HDL – C) 
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3) Increased non HDL cholesterol ( LDL + VLDL ) 
4) Increased small dense LDL particles 
5) Normal or borderline increase in LDL cholesterol (LDL – c) 
This type of dyslipidemia is most characteristic of type 2 diabetes . 
LDL profile in type 2 diabetes : 
         Glycation of apoprotein b (APO – b) decrease the divinity for LDL 
receptors and they may delay in LDL clearance. These glycated LDL are more 
susceptible to oxidation, and this oxidized LDL plays a key role in atherogenesis. 
Especially small dense LDL is highly atherogenic because of its susceptibility to 
oxidation.  A major determinant of LDL density distribution is the concentration 
of plasma TGL which accounts for approximately 75% of the variance of small 
dense LDL.  
Hypertriglyceridemia in type 2 diabetes: 
                        Hypertriglyceridemia is common in type 2 diabetes and it is 
usually accompanied by low HDL – c. Some triglycerides rich lipoprotein are 
atherogenesis especially IDL which accumulates in type 2 diabetes.  Fasting 
hypertriglyceridemia is associate with abnormal post prandial lipidemia which is 
associated with increased cardiovascular risk  .   
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Similarly hypertriglyceridemia leads to significant alteration in important 
lipoprotein species resulting in  a shift in LDL subtraction distribution and also 
low levels of HDL – c.  
Insulin resistance and lipid metabolism : 
                     Insulin plays a major role in regulatory steps in lipid and lipoprotein 
metabolism. There is a  reasonable hypothesis to explain the various components 
of diabetic dyslipidemia and their relationship to insulin resistance which 
include, increased hydrolysis of adipose tissue triglycerides results in enhance 
flux of non essential fatty acids(NEFA) to the liver. This is more important for 
VLDL production. Insulin resistance is associated with increased hepatic 
production of  large VLDL independent of NEFA flux.  The hepatic VLDL 
production is normally not suppressed post prandially resulting in competition 
for lipoprotein lipase with exogenous triglycerides carried on chylomicrons. This 
leads to accumulation of triglycerides which stimulates increased transfer of 
cholesterol ester transfer proteins(CETP) . As a result HDL and LDL are 
enriched in triglycerides. These particles are substrates for hepatic lipase activity 
which is increased in insulin resistance producing small dense LDL and small 
dense HDL.  
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Prothrombotic tendency of dyslipidemic patients : 
                         It has been well proved that there is  a close relationship between 
dyslipidemia and prothrombotic tendancy. What we have to know is whether 
lipid lowering therapy can reverse the coagulatory abnormalities in dyslipidemic 
patients . A small but significant reduction in factor VII antigens was seen with 
simvastatin. VWF was reduced following treatment with various lipid lowering 
drugs.  
        There is 20%  and  37% reduction in total and  LDL cholesterol following 
12 weeks treatment of fluvastatin , according to some studies. Significant 
correlations was found between reduction in factor VII with  total and LDL 
cholesterol levels. These   suggests that prothrombotic  tendancy in type 2 DM 
can be ameliorated by effective lipid lowering therapy.  
MANAGEMENT 
DIET MANAGEMENT  
         The diet management in diabetes is very controversial due to lack of 
consensus among the specialization in this field. Even today there are 
inconsistencies in the recommendations. The suggested diet to the patient should 
have the main objective of achieving normal weight. British physician produced 
31 
 
the black line diets , followed by the ‘exchange system of point system’ from 
USA descriptive of caloric contents of the carbohydrate food items. 
DIET IN TYPE 2 DIABETES 
As we know, the majority of diabetes is type 2, with an increased risk of 
morbidity and mortality related to atherosclerotic cardiovascular disease. As a 
result, diet that affect the serum lipids have become an important consideration in 
the management of diabetes. It is therefore appropriate to briefly analyse and 
summarise the present information on dietary fats.  
Reason for diet is to achieve the following goals: 
1) Weight control 
2) Blood sugar control 
3) Blood pressure control 
4) Lipid control 
5) To prevent short term and long term complications of diabetes. 
Achieving above goals is by the following balanced food choices 
1) Eat starch foods regularly (proper quantity) 
2) Eat more fruits and vegetables 
3) Eat high dietary fiber foods 
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4) Reduce animal or saturated fats 
5) Cut down on sugar 
6) Reduce salt 
MEDICAL NUTRITION THERAPY 
It is defined as the nutritional diagnostic therapy and counseling services for the 
purpose of disease management which are furnished by registered dietitian or 
nutritional professionals. This type of therapy has its own goals in the diet 
modification of diabetes mellitus. 
Goals of medical nutrition therapy are: 
1) To achieve and maintain blood sugar level in a normal range or as close to 
normal 
2) To achieve a lipid and lipoprotein profile that reduce the risk of vascular 
diseases. 
3) To prevent the rate of development of chronic complications of diabetes by 
modifying nutrient uptake and lifetstyle. 
GLYCEMIC INDEX 
It is the effect of carbohydrate on the blood sugar levels. The carbohydrates 
which breakdown very quickly during digestion and release glucose rapidly in 
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the blood stream have a high glycemic index. Similarly the carbohydrates that 
break down slowly and release glucose gradually have a low glycemic index. The 
current methods use glucose as the reference food, giving it a glycemic index of 
100. 
Low GI – 55 or less 
Medium GI – 56 to 69 
High GI – 70 and above 
Dietary fiber: 
          Consuming high fiber diet (>50 gm fiber/day) reduces glycemia in type 1 
diabetes and glycemia, hyperinsulinemia, lipemia in type 2 diabetes. Legumes, 
fiber rich cereals, fruits, vegetables and whole grain products are some of the 
fiber containing foods. 
Dietary fat and cholesterol: 
         Usually dietary fat and cholesterol provide 20 – 35 % of energy intake. In 
diabetes, the limit of dietary cholesterol is upto < 200mg/day. Limitation  of 
saturated fat to < 7% is necessary. Two or more servings of fish per week 
provide polyunsaturated fatty acids. 
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Proteins : 
In case of diabetic patients  with normal renal function , there is insufficient 
evidence to suggest the normal protein intake. In diabetics, these proteins can 
increase the insulin response without any increase in plasma glucose 
concentration. Therefore protein should not be used to treat acute or to prevent 
night time hypoglycemia. 
Alcohol : 
Alcohol consumption in men should be ≤3 standard drinks /day (or) <15 drinks 
per week.  In women, it is ≤ 2 standard drinks /day (or) < 10 drinks per week. 
Alcohol should be consumed with food in order to reduce the risk of nocturnal 
hypoglycemia in the individuals using insulin.  
NUTRITIONAL RECOMMENDATIONS FOR ADULTS WITH 
DIABETES 
Weight loss diet ( in prediabetes and type 2 DM) 
- Hypocaloric diet that is low – fat or low – carbohydrate 
Fat in diet 
- Minimal trans fat consumption 
Carbohydrate in diet 
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- Monitor carbohydrates intake in regards to calories 
- Sucrose containing foods may be consumed with adjustments in 
insulin dose. 
- Amount of carbohydrate diet determined by estimating grams of 
carbohydrates in diet 
Proteins in diet  
- As a part of optimal diet  
Other components 
- Non nutrient sweeteners 
- Routine supplements of vitamins, antioxidants  
 
 
INDIAN DIET IN RELATION TO FAT CONSTITUENTS 
                         25 – 30 gms/day of fat in Indian diet is from invisible fat sources 
like cereals, pulses, nuts, oil seeds, fresh coconuts and milk products. There has 
been a great shift from high carbohydrate diet to a high fat diet due to 
urbanization, as cooking makes easier and more palatable. At present , the 
carbohydrate to fat ratio in rural areas is 4 : 1 and this shifts approximately  1.5:1 
in urban areas. 
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                  It is more important to indicate the polyunsaturated fatty acid content 
of various cooking oils. From the table based on ICMR figures, it is clear that 
soyabean oil or mustard oil have sufficient omega 3 content .  
POLYUNSATURATED FAT CONTENT 
       Fat or oil Linoleic acid       
(omega 6) in 
g/100gms 
Linolenic  acid 
(omega 3) in 
g/100gms 
Total PUFA in 
g/100gms  
Sunflower oil            74            0.5             74.5  
Soyabean oil            52             5              57 
Cottonseed oil            50.3             0.4              50.7 
Corn oil            50             2              52 
Sesame oil            40             0.5               40.5 
Rice bran            33             1.6              34.6 
Groundnut oil            28             0.3              28.3 
Mustard oil            13             9               22 
Vanaspathi            3.4              -               3.4 
Ghee            1.6              0.5              2.1 
Coconut oil             2.2              -               2.2 
 
37 
 
ORAL HYPOGLYCEMIC AGENTS (OHA’s)  
The major defects that accounts for disturbance in type 2 diabetes are, impaired 
insulin action and decreased insulin secretion. The relative contribution of insulin 
deficiency vary considerably in causing hyperglycemia in diabetes. The goal of 
therapy in type 2  diabetes should not only improve the beta cell function, but 
also enhance the glucose utilization in the peripheral tissues. These oral drugs 
also have the potential to correct the hormonal and metabolic abnormalities in 
diabetes.  
SULFONYLUREA 
                     This oral hypoglycemic agent is being used for almost 50 years. The 
earliest sulfonylurea was tolbutamide which was introduced in 1957. 
Subsequently second generation sulfonylurea have been introduced which are 20 
– 100 times more potent than the first generation.  
                      Sulfonylureas act by binding to the so called sulfonylurea receptors 
(SUR – 1 )  on the pancreatic   beta call membranes causing depolarization, 
calcium influx and degranulation of secretory granules with insulin release. 
Therefore, these drugs primarily augment second phase of insulin secretion and 
has very less action on first phase. 
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     The delay in the first phase of insulin release in type 2 diabetes contributes to 
the excessive post prandial rise in blood sugar levels. The more rapid onset of 
action of sulfonylureas, the lesser is the delay in post prandial insulin release. 
Glipizide results in rapid post prandial insulin release and lowers post prandial 
glucose. In contrast glibenclamide exerts a better effect on fasting glucose.  This 
is attributed to the longer duration of action of glibenclamide and suppression of 
hepatic glucose production. Hence , where fasting glucose levels are high, 
glibenclamide may be preferred to glipizide and vice versa.  
 
   
      Drug  
Peak level 
in hours  
Half life 
in hours  
 
Metabolites  
  
  Excretion  
TOLBUTAMIDE 3 – 4  4.5 – 6.5  Inactive  Kidney 
CHLORPROPAMIDE  2 – 4 36  Active or 
unchanged 
Kidney  
GLIMEPRIDE 2 – 4  36 Active or 
unchanged 
Kidney 
GLIPIZIDE 1 – 3  2 – 4  Inactive  Kidney  
20%  bile   
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80% 
GLIBENCLAMIDE 4  10 Inactive and 
weakly active 
Kidney 50% 
bile 50% 
GLICLAZIDE 4 6 – 15  Inactive Kidney  
 
                          Sulfonylurea are mainly indicated in type 2 diabetes , especially 
in patients who still have adequate beta cell function and who fail to achieve 
glycemic control. 
                         Even among them, there are still reasons which are not clear  for 
about 15 – 20 % of patients who have no effect or little effect in glycemic control 
to sulfonylurea therapy. Moreover, the remaining patients who initially 
responded well to this therapy  loose responsiveness   after several months or  
years after therapy . Secondary failure, decreasing the beta cell function and 
increasing the insulin resistance are important disease related factors for 
sulfonylurea failure besides the duration of the disease. In a small percentage of 
patients, sulfonylurea therapy reduces remission in early stages. 
Sulfonylurea and hyperinsulinemia :  
             Insulin resistance and hyperinsulinemia causes increases sympathetic 
activity and sodium retention thereby causing hypertension .  It also causes 
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hypertriglyceridemia and lowers the HDL cholesterol. It also promotes the 
proliferation of arterial smooth muscle cells and collagen synthesis in the 
vascular walls. Administration of sulfonylureas improves the insulin action on 
peripheral tissues, correct insulin resistance and hyperinsulinemia.  
BIGUANIDES  
                    Metformin, phenformin and buformin belongs to this group. The  
later two drugs are withdrawn long back. Metformin is an old, but still the best 
agent of choice to start with in treatment of type 2 diabetes. Its efficacy, safety 
profile and its capacity to be associated with other anti diabetic agents makes 
metformin the first glucose lowering drug of choice in diabetes management.  
                  The principle site of action is in the liver and muscles. The effect of 
metformin on liver is mediated by activation of liver kinase B1. This drug is 
equally effective in normal weight patients,    contrary to its widespread 
perception in our country that it is preferred in obese patients. 
Metformin in different situations:  
1) Childhood and adolescence  - the beneficial effect has been documented in 
this age group. There are studies which suggest improvement in metabolic 
control in poorly controlled children and adults with type 1 diabetes , when 
metformin is added along with insulin therapy. 
41 
 
2) Pregnancy – metformin crosses the placenta and thus concerns regarding 
its safety in mother and fetus have limited its use in pregnancy. There are 
studies which showed , infants of mother exposed to metformin in utero 
had reduction in insulin resistance  examined 2 years after birth.  
3) Poly cystic ovarian disease – metformin in PCOS leads to ovulation 
leading to achievement of pregnancy. This  drug can be continued after 
conceiving  where studies didn’t show any fetal loss if the drug is being 
continued. 
4) Metformin in cardiovascular protection – this drug is often associated with 
decreased LDL cholesterol, fasting as well as post prandial decrease in 
TGL and free fatty acids thereby having an cardioprotective action. 
5) Metformin and cancer – recent studies have shown that, metformin reduces 
tumorigenesis and cancer cell growth probably through reduction of 
hyperinsulinemia and IGF – 1  levels.  
THIAZOLIDINEDIONES  
                     Thiazolidinediones are potent insulin sensitisers, that act through 
the nuclear receptor, peroxisome  proliferator activated receptor gamma. This 
PPAR gamma mediated transcriptional effects have been shown to improve 
whole body insulin sensitivity.  
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                    Drug used are, troglitazone, rosiglitazone and pioglitazone. Among 
these drugs, troglitazone have been banned in the year 2000, due to its fatal 
hepatotoxicity after which rosiglitazone was introduced. Pioglitazone  is the third 
drug used that has been shown to improve insulin sensitivity.  
                   Eventhough pioglitazone has cardiovascular benefits when compared 
to rosiglitazone , it has its own side effects. Some of the common side effects are 
weight gain, edema, congestive cardiac failure  because of fluid retention and 
plasma volume expansion. Some other factors which contribute to edema are, 
vasodilatation,  increased vascular permeability and increase in renin and 
aldosterone activity.  There are studies which showed association between use of 
glitazones and occurrence of macular edema. Therefore it has to be withdrawn if 
macular edema  is suspected.  
GLP – 1 ANALOGUES  
                     This incretin hormone GLP – 1 is secreted from intestinal L cells , 
in distal ileum and colon in response to food intake. The effect of subcutaneous 
injection of GLP – 1 analogue is very short acting due to N terminal degradation 
by the enzyme dipeptidyl peptidase IV (DPP – IV), restricting its cardiac use.  
Based on its duration of action this group of drugs are divided into  
a)  Short acting  - duration of action is < 24 hours  
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                     e.g., exenatide and lexisinatide  
     b) long acting -  duration of action > 24 hours.  
                                e.g., liraglutide ( once daily) 
                                       exenatide LAR (once weekly) 
This  drug has been proved to be non inferior to metformin, glitazones, 
sulfonylureas and insulin and therefore they are currently approved in treatment 
of type 2 diabetes as a monotherapy and add on therapy to the existing 
medication. This drug has beneficial effect on cardiovascular system, lipid 
profile, obesity and also in central nervous system.  
List of GLP -  1 ANALOGUES  
 
     Drug  
Approval 
status 
 
    Dose  
 
Frequency  
HbA1c 
reduction 
Effect on 
weight  
Exenatide Approved  5 – 10mcg Twice daily 1- 1.9 % Yes 
Liraglutide  Approved 0.6 –
1.8mg 
Once daily 0.9 – 1.6 % yes 
Exenatide 
LAR 
Approved 2mg Once 
weekly 
1.5% Yes 
Lixisenatide  Awaited 20mg Once daily 0.74% Yes 
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Albiglutide  Awaited 30mg Once 
weekly 
0.57% Yes 
Dulaglutide  Awaited >1mg Once 
weekly 
1.28 – 
1.52% 
Yes 
Taspoglutide  Halted - -  1.1% Yes 
Semaglutide  Awaited  1mg Once 
weekly 
Awaited  Yes 
 
 
DIPEPTIDYL PEPTIDASE  - IV INHIBITORS (GLIPTINS) 
                          DPP – IV inhibitors  are novel antidiabetic drugs based on the 
incretin therapy. These drugs help in decreasing the degradation of endogenous 
incretin hormone .  
                         Gliptins as a monotherapy  generally carries a mow risk of 
interprandial hypoglycemia . Similarly gliptins are   generally regarded as weight 
neutral agents and may assist a small amount of weight loss. Four drugs have 
been introduced till now.  
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a) Sitagliptin 
b) Vildagliptin  
c) Saxagliptin 
d) Linagliptin   
All the drugs have been approved except vildagliptin. Gliptins have demonstrated 
similar reduction in fasting , post prandial glucose levels and Hb A1c as 
compared to sulfonylurea, alpha glucosidase inhibitors, except for metformin , 
because of which metformin is said to be the first line drug to be started as a 
monotherapy. Therefore gliptins are preferred 2nd line drugs for monotherapy.  
LIST OF DPP – IV INHIBITORS  
       Drug  Absorption        Dose  Elimination 
route in 
percentage  
Sitagliptin 87% 100mg OD Renal (80% 
unchanged ) 
Vildagliptin 85% 50 mg BD Renal (22% as 
parent, 55% as 
primary 
metabolite) 
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Saxagliptin 67% 5mg OD Renal(>70% as 
unchanged)  
Linagliptin  30% 5 mg OD Biliary (>70% 
unchanged as 
parent, <6% via 
kidney)  
 
ALPHA – GLUCOSIDASE INHIBITORS  
1) Acarbose 
2) Voglibose  
Mechanism of action of alpha glucosidase inhibitors involves block of the 
enzyme alpha glucosidase in the intestine which normally clears 
carbohydrates into absorbable monosaccharides.  
INSULIN SECRETAGOGUES – PRANDIAL GLUCOSE REGULATORS 
Repaglinide – it is  a benzoic acid derivative which stimulate beta cell function. 
Prandial glucose regulators act on a unique binding site at beta cell. The 
compound is very potent, very rapid, and short acting . repaglinide is capable of 
causing a substantial reduction in post prandial blood glucose level. The 
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treatment is tailored to the meals, meaning that the dose is preprandial and 
omitted if a meal is omitted.  
            Repaglinide is metabolized in liver . insulin sensitisers could be used for 
obese patients suffering from insulin resistance and prandial glucose regulators 
such as repaglinide could be used for type 2 diabetic patients who cannot produce 
sufficient insulin and still have some beta cell function. 
ROLE OF INSULIN IN TYPE 2 DIABETES 
 
               Type 2 diabetes constitutes nearly 95-97% of all diabetes. The 
successful management of type 2 diabetes involves around an individual tailored 
nutritional plan, exercise regimen, use of oral agents and or insulin. 
                Tissues insensitivity to insulin and impaired insulin secretion are the 
pathogenetic factors underlying type 2  diabetes.  The primary defect is tissue 
insensitivity to insulin. It becomes clear that it soon leads to higher blood glucose 
level.  
                Macrovascular complications due to atherosclerosis are the major 
problem in type 2 diabetes. Long term hyperglycemia is a significant predictor 
for excess cardiovascular mortality in type 2 diabetes. 
                 Why should hyperglycemia be treated in type 2 diabetes is to relieve 
symptoms and improve subjects well bring. Glucose toxicity as  adverse effects 
on insulin resistance and beta cell function. 
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             DCCT provides strong evidence that tight glycemic control prevents 
microvascular complications. Hyperglycemia is a predictor of excessive 
cardiovascular mortality. 
 
INITIATING  INSULIN THERAPY IN TYPE 2 DIABETES  
               Apart from temporary indications of insulin therapy, long term insulin 
therapy is always challenging. In case if the patient is on oral hypoglycemic 
agent with failure, adding  a basal insulin a shot while continuing oral agents is 
simply effective way of initiating insulin therapy. 
Some of the indications for insulin use in type 2 diabetes are : 
a) Primary oral agent failure 
b) Secondary oral agent failure 
c) Peri operative 
d) Pregnancy 
e) Acute or chronic sepsis 
f) Acute medical or surgical event 
g) Major organ failure 
h) Glucotoxicity 
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Hypoglycemia and weight gain  - these are the 2 main complications of insulin 
therapy. Eventhough basal bolus insulin therapy is a step forward to 
physiological insulin secretion, majority of studies have reported incidence of 
hypoglycemia. The following steps to be followed to reduce incidence of 
hypoglycemia. 
a) Dietary discipline 
b) Patient education 
c) Self monitoring of blood glucose 
d) Sick day rule management 
e) Usage of insulin analogues 
f) Lowering the HbA1c target in high risk groups 
g) Usage of insulin sensitisers over insulin secretogogues 
The current targets for metabolic control in type  2 diabetes should be achieved 
by OHA, otherwise insulin should be started. 
Blood glucose in mmol/l Good Acceptable Poor 
Fasting 4 – 6  ≤8 ≥8 
Post prandial  4 – 8  ≤10 ≥10 
HbA1c in % 4 – 6  6 – 8 ≥8 
BMI  <25  <27 ≥27 
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INSULIN INITIATION, INTENSIFICATION AND CONTINUATION IN 
T2DM 
                        All patients with type 2 diabetes have both inadequate insulin 
secretion and also insulin resistance. Most of the diabetic patients, especially 
type2 diabetics, require treatment to achieve and maintain a target HbA1c 
between 6.5-7.  
                      Eventhough the pharmacological management of type 2 diabetes 
start with oral medications, majority of the patients require exogenous insulin 
therapy at one point of time. Although insulin therapy is prescribed on an 
individualized  basis, treatment usually begins with basal insulin added to 
background of oral agents. Currently  available insulin analogues may represent 
an important therapeutic alternative for many patients. 
 Glucose dependant insulin secretion occurs in 2 phases.  
a) In first phase, insulin response occurs more quickly within 3 – 5 mins 
period immediately after eating and ends rapidly. This phase of response is 
normal in genetically predetermined and usually abnormal in subjects with 
a first degree relative with diabetes.  
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b) Fifteen minutes after carbohydrates are consumed and the process of 
digestion begins, 2nd phase of insulin response in initiated. During  this  
phase , beta cells produce and secrete insulin until all carbohydrates has 
been absorbed from gastro intestinal tract and the plasma glucose levels 
have been normalized. This phase plateaus in 2 – 3 hours , yet the post 
absorptive state can last upto 6 hours.  
Prolonged exposure to even moderately elevated glucose is associated with beta 
cell desensitization , increased apoptosis, delay in first phase response and 
attenuated second phase of response.  
WHEN TO START INSULIN ? (INDIAN GUIDELINES)  
a) At diagnosis, fasting glucose > 200mg/dl , post prandial glucose > 
300mg/dl with HbA1c > 9% 
b) After oral drug failure, despite receiving optimal dose of 2 or 3 OAD’s, 
fasting glucose > 150 mg/dl , post prandial glucose > 200mg/dl with 
HbA1c levels of > 8.5% 
INITIATION OF INSULIN WITH BASAL VERSUS PREMIX INSULIN  
       At present the most common approach to initiate insulin are with a basal 
insulin analogue usually at bed time  or with a premix insulin usually with 
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breakfast and dinner. There are 3 important exceptions to initiate insulin with 
basal insulin. they are,  
a) Patients with high HbA1c (>8.5%), who may not be able to reach the 
HbA1c goal solely with basal insulin since they also need insulin ‘cover’ 
for their post prandial glucose. 
b) Patients with lower compliance who are often hesitant to titer their insulin 
doses. 
c) Patients with relatively low fasting or post prandial glucose and relatively 
high HbA1c suggests high post prandial hyperglycemia.  
PREMIX VERSUS BASAL BOLUS REGIMEN 
Premix insulin analogues Basal plus/ basal bolus 
Patient preference Type 1 diabetes (any age) 
Older age Younger age 
Need assistance with injections Highly motivated and compliant 
Organized lifestyle Active lifestyle 
2 meals a day or evening main meal High variability in eating habits. 
 
INSULIN ANALOGUES - Why do we need insulin analogues? 
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a) Initially, the earliest insulin used was a soluble (regular) insulin, which is a 
animal derivative, impure, because of which it was often associated with 
insulin allergy, lipodystrophy and antibody mediated insulin resistance.  
b) Combination of insulin with zinc or basic proteins(protamine) also lead to 
delayed absorption of insulin from the subcutaneous sites leading to 
development of longer acting lente and ultra lente insulin.  
c) Similarly , the conventional longer acting insulin (NPH insulin) use is 
limited by lack of 24 hour effect, thereby need of 2 injections in majority 
of the patients and  a delayed peak effect , have associated with increased 
risk of nocturnal hypoglycemia.  
                       All of these above limitations, have lead to the development of 
insulin analogues which are designed to improve on the subcutaneously 
administered pharmacokinetic and pharmacodynamic inadequacies of 
conventional human insulin. The pharmacodynamic effect of the insulin 
analogues of native insulin better approximate endogenous insulin secretion and 
have expected to result in superior clinical end points.  
RAPIDLY ACTING INSULIN ANALOGUES  
            Insulin Lispro ,Aspart and Glulisine are the 3 rapidly acting insulin 
analogues which are approved for clinical use as bolus or meal time insulin.  
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            Because of the structural changes in the amino acid sequence of these 
insulin, they have a  faster onset of action ( 10 – 15 mins) , peak of action (0.5 – 
2 hours) , shorter duration of action (3 – 4 hours) and less variability between 
injection site in comparison with regular insulin. 
            These short acting insulin analogues also have the benefits of improved 
normalization of post prandial glucose, decreased hypoglycemic events and 
enhancement in quality of life. Potential clinical disadvantages are, risk of early 
post prandial hypoglycemia and preprandial hyperglycemia. 
LONG ACTING INSULIN ANALOGUES      
This group includes Insulin Glargine and Insulin Detemir.  These insulin 
analogues have undergone structural alterations allowing for prolonged 
absorption following a subcutaneous injection and relatively peakless 24 hours 
action profile, which is much more analogous to basal insulin release when 
compared to NPH.  
               Both Glargine and Detemir have a onset of action with in 1- 3 hours of 
administration and a relatively peakless , dose dependant, mean duration of 
action of approximately 24 hours. One more advantage of these long acting 
analogues is that, both have lesser inter individual variability in absorption rates 
55 
 
from injection sites along with reduced incidence of hypoglycemia, especially 
nocturnal hypoglycemia when compared to NPH insulin.  
LATEST INSULIN ANALOGUE – DEGLUDEC 
- It is the latest approved longer acting insulin analogue.  
Various trials have been conducted comparing degludec with other  longer acting  
insulin analogues, which showed that degludec is associated with lower rates of 
hypoglycemia in type 1 diabetes mellitus and superior post prandial glucose 
control compared with glargine in those with type 2 diabetes mellitus. 
                 Development of insulin analogues has significantly contributed to 
improving glycemic control in patients with diabetes. The future of insulin 
analogues is bright with several new drugs in the pipeline. However, the use of 
insulin analogues in our country may be limited because of high cost .  
PROPERTIES OF INSULIN SECRETOGOGUES 
CLASS/GENERIC NAME Daily dose in mg Duration of 
action(h) 
SULFONYLUREAS   
Glimepride 1 – 8  24 
Glipizide 5 – 40  12 – 18 
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Glyburide 1.25 – 20  12 – 24  
MEGLITINIDES   
Repaglinide 0.5 – 16  2 – 6  
Nateglinide 180 – 360  2 – 4 
GLP – 1 ANALOGUES   
Exenatide 0.01 – 0.02  4 – 6  
Liraglutide  0.6 – 1.8  12 – 24  
DPP – IV inhibitors   
Saxagliptin 2.5 – 5  12 – 16  
sitagliptins 100 12 – 16  
Vildagliptin  50 – 100  12 – 24  
 
 
PROPERTIES OF INSULIN PREPARATIONS  
PREPARATION  ONSET 
in hours 
PEAK in 
hours  
DURATION 
in hours  
Aspart  < 0.25 0.5-1.5 3 – 4  
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Glulisine  <0.25 0.5-1.5 3 – 4  
Lispro  <0.25 0.5-1.5 3 – 4 
Regular  0.5 – 1.0  2 – 3  4 – 6  
Detemir  1 – 4  Upto 24 hrs 
Glargine  1 – 4    Upto 24 hrs 
NPH  1 – 4  6 – 10  10 – 16  
75/25-75%protamine lispro, 25%lispro <0.25 1.5 10 – 16 
70/30-70%protamine aspart, 
30%aspart 
<0.25 1.5 10 – 16 
50/50-50%protamine lispro,50%lispro <0.25 1.5 10 – 16 
70/30-70%NPH,30%regular 0.5 – 1 Dual 10 – 16  
 
 
DIABETIC DYSLIPIDEMIA 
            Individuals with diabetes mellitus have various forms of dyslipidemia. 
Generally in type 1 diabetes mellitus, dyslipidemia is uncommon if the patient is 
under good glycemic control. Conversely  in case of type 2 diabetes mellitus 
eventhough if the patient is in good glycemic control, dyslipidemia is more 
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common. Because of the additive cardiovascular risk of hyperglycemia and 
hyperlipidemia, lipid abnormalities in case of diabetes should be aggressively  
treated.  
           The most common dyslipidemic pattern seen in diabetes is increased 
triglycerides and reduced HDL cholesterol. Diabetes itself doesn’t elevate the 
levels of LDL, but the small dense LDL particles found in diabetes are  more 
atherogenic because they are more easily glycated and susceptible to oxidation. 
Eventhough increased LDL is not a common feature of type 2 diabetes, its 
presence indicates a underlying lipoprotein abnormality or development of 
diabetic nephropathy. Almost all treatment studies of diabetic dyslipidemia have 
been performed in individuals with type 2 diabetes because of greater frequency 
of lipid abnormalities in this form of diabetes. 
                  Large prospective studies of primary and secondary intervention for 
CHD have included some individuals with type 2 diabetes subset analysis have 
consistently found that reduction in LDL reduce the cardiovascular events in 
individuals with diabetes. No prospective studies have addressed similar 
questions in individuals with type 1 diabetes. Since the frequency of 
cardicovascular disease is low in children and young adults with diabetes, 
assessment of CV risk should be incorporated into guidelines discussed below.  
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               Based on the guidelines by the American diabetes association and 
American heart association, the following should be the priorities in the 
treatment of dyslipidemia in a patient with diabetes. 
a) Lower the LDL cholesterol 
b) Raise the HDL cholesterol 
c) Decrease the triglycerides  
Initial therapy in all forms of dyslipidemia should focus on the dietary 
modifications as well as life style changes which are being practiced for  non 
diabetic individuals like smoking cessation, blood pressure control, weight loss 
and increased physical activity. 
                The dietary recommendations for individuals with diabetes mellitus are 
similar to those advocated by the national cholesterol education program and it 
includes increased monosaturated fats and carbohydrates and reduced saturated 
fats and cholesterol. Though viewed as important, the response to dietary 
alterations if often modest. Improvement in glycemic control will lower the 
triglycerides and have  a modest beneficial effect on HDL.  
                    According to American heart association, the target lipid values in a 
diabetic individual (age > 40) should be as follows : 
a) LDL < 2.6mmol/l (100mg/dl) 
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b) HDL > 1 mmol/l (40mg/dl) in men and > 1.3 mmol/l (50mg/dl) in women 
c) Triglycerides < 1.7 mmol/l (150 mg/dl)  
If the patient is more than 40 years, American  diabetes association recommends 
addition of statin irrespective of the LDL levels in patients with coronary heart 
disease and those without CHD, but has the risk factors for developing coronary 
artery disease. If the patient is known to have coronary artery disease, American 
diabetes  Association   recommends the LDL goal to be < 1.8 mmol/l (70mg/dl) 
as an option.  
HYPOLIPIDEMIC AGENTS  
 BILE ACID BINDING 
RESINS 
NICOTINIC ACID 
Dose  Cholestyramine  8 – 
12gm in BD or TDS 
Niacin 50 – 100 mg tid 
initially, then increase to 
1 – 2.5 gm tid, later 0.5 – 
1 gm tid 
Mode of action  Interrupts inter hepatic 
circulation of bile acid. 
Increase the synthesis of 
new bile acids 
Decrease the synthesis of 
VLDL and LDL 
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Lipoprotein class 
affected  
Decrease LDL cholesterol  
Increase HDL and TGL  
Decrease VLDL by 35% 
Decrease LDL 15-20% 
Side effects Constipation, nausea, 
bleeding 
Flushing, tachycardia, 
arryhtmias,  pruritis, dry 
skin, nausea, diarrhea, 
hyperuricemia, peptic 
ulcer, glucose 
intolerance, hepatic 
dysfunction  etc.  
Contra indications  Biliart tract obstruction, 
gastric outlet obstruction, 
hypertriglyceridemia 
Peptic ulcer disease, 
cardiac arryyhtmias, 
gout, diabetes, liver 
disorders. 
 
 HMG Co A 
REDUCTASE 
INHIBITORS 
FIBRIC ACID 
DERIVATIVES  
Dose Lovastatin 10-8-mg/d 
Pravastatin 10-40mg/d 
Gemfibrozil 600mg BD 
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Simvastatin 5-40mg/d 
Fluvastatin 10-80mg/d 
Mode of action  Decrease the cholesterol 
synthesis, increase LDL 
receptors 
Increase LPL 
Increase TGL hydrolysis 
Decrease VLDL 
synthesis 
Increase LDL catabolism 
Lipoprotein class 
affected 
Decrease LDL 30 – 40% 
Decrease VLDL 
Decrease TGL 
Increase or decrease LDL 
Increase HDL 
Side effects  Abnormalities in liver 
function  
Increased lithogenicity of 
bile, nausea , liver 
function abnormalities  
Contraindications Increased myositis in 
patients with renal failure 
and in patients with 
gemfibrozil, nicotinic 
acid or cyclosporine.  
Hepatic or biliary 
disease, renal 
insufficiency. 
 
 
63 
 
ROLE OF EXERCISE IN DIABETES MANAGEMENT 
              Due to favourable metabolic adaptations from regular exercise , physical 
activity gives a promising strategy in improving the complex disturbances which 
are characteristically seen in development andprogression of type 2 diabetes. 
Most of the beneficial effects of exercise is mainly  due to improved insulin 
resistance.  
PATHOPHYSIOLOGY OF EXERCISE IN TYPE 2 DIABETES 
              A single bout of exercise can lead to an acute increase in the glucose 
uptake by the working muscles , where most of the glucose is oxidized to supply 
energy. Regular physical training performed over long period lead to chronic 
muscular adaptations. Various comparative studies of trained and untrained 
subjects indicate that , regular exercise induces several cytoplasmic and 
mitochondrial enzymes and increase the expression of glucose transporter 
system, particularly GLUT – 4 in skeletal muscles.  
                         The number and binding affinity of insulin receptors as well as 
capillary density of skeletal  muscles are increased . this shows that, regular 
exercise can increase insulin sensitivity not only in the periphery in muscles but 
also centrally in liver. Most of the effects are primarily induced by aerobic 
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exercise, which may increase the insulin sensitivity mostly by increasing the 
skeletal muscle mass.  
                It is a  well established fact that, macrovascular complications 
contribute to the poor prognosis of type 2 DM, not only the glycemic control but 
also the other factors like dyslipidemia and hypertension must be controlled. 
          Many of these factors can easily by controlled by regular moderate 
physical activity such as walking. The stimulus were these improvements appears 
to increase physical activity enery expenditure by 1000kcal/week. Even the new 
physical activity recommendations by the centre of disease control (CDC) and 
American college of sports medicine state that, every adult should do, 30 minutes 
or more of moderate intensity physical activity preferably all days of the week.  
DIABETES AND PATIENT EDUCATION 
There is often a true fact that diabetes affects several aspects of life and ideally 
requires the patients to make several changes. Simply it affects diet, lifestyle, 
physical well being, mental state, economic conditions, sexual and marital life. 
Therefore the outcome variables that need attention are ,  
a) Quality of life 
b) Life span 
c) Mortality rates 
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d) Biochemical outcomes 
e) Knowledge, attitude and practice 
f) Skill. 
CONTENTS OF PATIENT EDUCATION PROGRAMMES 
PRIMARY SECONDARY TERTIARY 
Overview Self insulin  Travel 
Meal plans Adjustments and 
supplements 
Pregnancy 
Insulin injection technique Sick day guidelines in 
detail  
Chronic complications 
Monitoring blood glucose 
and ketones 
Foot care  
Hypoglycemia Meal exchanges   
Sick day guidelines – basic   
 
As the first step of patients education, the educator should assess the patients 
perception about the disease. At the same time, the patient should know why they 
should know about the disease, what are the target of the education and what are 
the long term goals . 
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          There are few principles of education. Neither unnecessary details nor dull 
superficial information could benefit the patients. Message should be given in a 
non threatening manner. At the same time, the patient should feel free and 
express doubts.  
METHODOLOGY OF TEACHING 
1. Verbal  
a) Diabetic lecturing  
b) Discussion/ seminar / group discussion 
c) Demonstration 
2. Print material  
a) Magazines for the lay public 
Eg., balance, challenge, diabetic news etc.,  
b) Lay books  
c) Lay articles 
d) Cartoon books 
3. Audio visual aids 
a) Films / videos 
b) Flip charts 
c) Slide talks 
4. Other methods 
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a) Games 
b) Plays 
c) Dramas 
d) Role playing 
e) Computer programs  
f) Quizzes 
g) Contracting  
5. Residential camps  and diabetic melas like  
a) Camps organized by juvenile diabetic foundation. 
Atlast it is very important to educate the family members in the management of 
diabetes care.  
a) The family members should attend diabetes education classes along with 
the affected family member. 
b) Provide the family with reading materials.  
c) Practice skills at home with your family. Perform finger sticks for blood 
glucose, inject saline into a orange doll, and review the treatment for 
hypoglycemia so that the family members can understand what you go 
through and also carry out in case of emergencies. 
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d) Make sure family members know your meal and medication schedule . 
they have to be explained how we are planning to handle any achedule 
changes so that they are prepared in the event of complications. 
e) Encourage any family members who is having trouble coping with your 
having diabetes to seek counseling to discuss his or her feelings and 
anxieties.  
f) Active participation of the family members involves more than just 
explaining what was taught, and they have the opportunity to ask questions 
to the diabetes educator. Family members should discuss , ask diabetes 
nurse educator to clarify any discrepancies .  
g) Persons with diabetes having complications like nephropathy, retinopathy 
and cardiovascular diseases have to be educated more, as they are more 
affected both physically and mentally because, with each complication, 
financial burden of the family  increases.  
 
GUIDELINES FOR ONGOING MEDICAL CARE FOR DIABETIC 
PATIENTS 
Self monitoring of the blood glucose (individualized frequency) 
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HbA1c testing 2 – 4 times / year 
Patient education in diabetes management  (annual) 
Medical nutrition therapy (annual)  
Eye examination (annual) 
Foot examination ( 1-2 times/year  by physician and daily by patients)  
Screening for diabetic nephropathy (annual) 
Blood pressure measurement (quarterly ) 
Lipid profile and creatinine (annual) 
Influenza / pneumococcal vaccinations 
Consider antiplatelet therapy. 
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MATERIALS AND METHODS 
PLACE OF THE STUDY  
                  The study was conducted at Government Rajaji Hospital, Madurai 
Medical college, Madurai. 
PERIOD OF STUDY  
                April 2014 to September 2014 
STUDY DESIGN 
                  Observational type of study 
CONSENT 
                 Informed written consent was obtained from all patients.  
STUDY POPULATION 
               50 patients who are known case of type 2 diabetes mellitus were 
selected from Department of Diabetology , Government Rajaji Hospital , 
Madurai  
INCLUSION CRITERIA 
a) Known type 2 diabetes patients 
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b) Age > 35 years, both sexes 
c) BMI > 25 
EXCLUSION CRITERIA 
a) Self reported diabetes mellitus  
b) Dyslipidemia 
c) Pregnancy 
d) Hypothyroidism 
e) Hypertension 
f) Renal failure 
g) Smokers and alcoholics 
h) Patients on thiazolidinediones  
METHODOLOGY  
          50 patients who are known case of type 2 diabetes mellitus were analysed 
for this study.  
          A thorough clinical evaluation was made and detailed history, blood 
pressure, height, weight, waist and hip circumference  were taken .  
a) Fasting lipid profile was done by enzymatic methods like zaks method, 
and spot urine sample for microalbuminuria were taken. 
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b) Waist circumference was measured at the midpoint between lower costal 
margin  and anterior superior iliac spine in mid axillary line.  
c) Hip circumference was measured at the level of greater trochanter of 
femur.  
          Waist hip ratio (WHR) ≥ 0.90 in males and  ≥ 0.80 in female are taken to 
be significant .  
d) Anthropometric measurements are done to calculate BMI and WHR .  
BMI > 25 for males and females are taken to be significant to indicate obesity.  
e) Visceral fat thickness (VFT) was measured by ultrasound. The following 
procedures are made out in measuring the visceral fat thickness. 
- Patient should be in fasting 
- Bowel preparation done by enema  
- Patient in supine posture with full expiration 
- USG  probe is kept 5 cm above the umbilicus in the midline joining 
xiphisternum and umbilicus 
- Distance between the internal surface of rectus abdominis muscle and 
posterior wall of aorta are measured.  
- Frozen images are taken. Atleast 3 measurements are taken and its 
mean in calculated to avoid measurement errors.  
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VISCERAL FAT THICKNESS MEASUREMENT 
 
  
1   - distance between the internal surface of rectus abdominis and aorta 
2  - aorta  
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OBSERVATIONS AND RESULTS  
In the present study, 50 patients of type 2 diabetes were selected and studied. 
They were subjected to detailed clinical examination. The  age distribution is as 
follows. 
TABLE I 
AGE DISTRIBUTION: 
 
 
 
 
AGE IN YEARS NO.OF CASES 
< 40 3 
41 – 50 20 
51 – 60 18 
> 60 9 
Total 50 
75 
 
 
 
 
This is the bar diagram showing the age distribution of the study . 50 males and 
50 females were taken equally. Most of the patients fall in between the age group 
of 41 – 50. The second highest group  was between 51 – 60. 
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TABLE II 
SEX DISTRIBUTION OF THE STUDY 
SEX NO.OF CASES 
Male 25 
Female 25 
Total 50 
 
 
 
 
 
 
  
As previously mentioned , 25 males and 25 females were taken equally for the 
study. They were selected according to the inclusion and exclusion criteria of the 
study. This picture shows the sex distribution of the study. 
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TABLE III 
BMI DISTRIBUTION IN TYPE 2 DIABETIC SUBJECTS 
 
BMI No.of cases 
<  26 7 
26.1 to 28.0 27 
28.1 to 30.0 8 
>  30 8 
Total 50 
 
 
 
 
 
 
 As per inclusion criteria, subjects were selected with BMI >
shows the BMI distribution of the study. Among 50 patients selected , around 27 
patients fall in BMI between 26 
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TABLE IV 
CORRELATION BETWEEN VISCERAL FAT THICKNESS AND 
TOTAL CHOLESTEROL IN TYPE 2 DIABETIC SUBJECTS. 
 
 
Mean SD p value 
Visceral Fat 6.08 0.97 
Cholesterol 220.72 34.43 < 0.001 
 
 
 
 
 
 
 
 
 
 This diagram shows the correlation between the mean visceral fat thickness and 
total cholesterol levels. The mean visceral fat thickness in overall subjects was 
6.08. The  total cholesterol mean was 220.72, which was almost in the high 
normal range.  
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TABLE V 
CORRELATION BETWEEN VISCERAL FAT THICKNESS AND 
TRIGLYCERIDES IN TYPE 2 DIABETIC SUBJECTS. 
 
 
Mean SD p value 
Visceral Fat 6.08 0.97 
TGL 178.3 41.87 < 0.001 
 
 
 
 
 
 
 
  
This  diagram shows the correlation between mean visceral fat thickness and  
triglycerides level in type 2 diabetes subjects. The mean visceral fat thickness 
among 50 patients was 6.08. The mean triglycerides level was 178.3, which was 
high. Among the 50 subjects, 16 patients who had their VFT between 5.6 
had a mean TGL level of 176.6, and patients who had VFT of more than 6.5 had 
a mean TGL levels of around 210.4. 
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TABLE VI 
COMPARISON BETWEEN MEAN VISCERAL FAT THICKNESS AND 
MEAN OF LIPID PROFILE 
 
Visceral fat and lipid profile  Mean 
Visceral Fat 6.08 
Cholesterol 220.72 
TGL 178.3 
HDL 39 
VLDL 35.67 
LDL 145.32 
 
 
 
  
This diagram shows the overall mean of lipid profile. The mean visceral fat 
thickness was 6.08 in 50 subjects. The mean total cholesterol was 220.72, mean 
triglycerides level was 178.3 which was very high, mean HDL was 39, mean 
LDL was 145.32. Therefore th
thickness with triglycerides and LDL. 
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TABLE VII 
CORRELATION BETWEEN VISCERAL FAT THICKNESS AND HIGH 
DENSITY LIPOPROTEINS IN TYPE 2 DIABETIC SUBJECTS 
 
Mean SD p value 
Visceral Fat 6.08 0.97 
HDL 39 2.67 < 0.001 
 
 
 
 
 
  
 
This picture shows the correlation between mean visceral fat thickness and mean 
high density lipoproteins level. The mean visceral fat thickness was 6.08 , 
whereas the mean JDL level was 39, which was almost in a normal range. Unlike 
triglycerides level, HDL didn’t show an positive correlation with visceral fat 
thickness.  
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TABLE VIII 
CORRELATION BETWEEN VISCERAL FAT THICKNESS AND VERY 
LOW DENSITY LIPOPROTEINS LEVEL IN TYPE 2 DIABETIC 
SUBJECTS 
 
 
Mean SD p value 
Visceral Fat 6.08 0.97 
VLDL 35.67 8.47 < 0.001 
 
 
 
 
 This diagram  shows the correlation between the mean visceral fat thickness and 
mean very low density lipoprotein levels. The mean visceral fat thickness was 
6.08, whereas the mean VLDL  levels was 35.67. 
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TABLE IX 
CORRELATION BETWEEN VISCERAL FAT THICKNESS AND LOW 
DENSITY LIPOPROTEINS IN TYPE 2 DIABETIC SUBJECTS. 
 
Mean SD p value 
Visceral Fat 6.08 0.97 
LDL 145.32 31.41 < 0.001 
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This picture shows the comparison in the mean of visceral fat thickness and low 
density  lipoproteins  level. As already mentioned the mean visceral fat thickness 
in 50 subjects was 6.08. The mean LDL levels was 145.32, which was almost in 
the high normal range. Moreover , subjects with VF between 5.6 – 6.5 had a 
greater LDL levels of around 170. Therefore there is a strong positive correlation 
between increased visceral fat thickness and LDL levels.  
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TABLE X 
COMPARISON OF VISCERAL FAT THICKNESS AND BMI IN TYPE 2 
DIABETES SUBJECTS 
 
Mean SD p value 
Visceral Fat 6.08 0.97 
BMI 27.61 1.81 < 0.001 
 
 
 
 
 
 
 
 
 This picture shows the correlation between mean visceral fat thickness and the 
mean BMI of the 50 subjects taken in this study. Eventhough the subjects with 
BMI > 25 was taken as the inclusion criteria, the mean BMI was 27.61 among 
the 50 subjects. Around 27 patients fall in BMI between 26 
visceral fat thickness was 6.08. 
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TABLE XI 
COMPARISON BETWEEN VISCERAL FAT THICKNESS AND 
MICROALBUMINURIA IN TYPE 2 DIABETIC SUBJECTS 
 
 
 
 
Microalbuminuria vs 
Viseral Fat Mean SD p value 
Present  (13) 7.22 0.59 < 0.001 
Nil  (37) 5.68 0.74 
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This picture shows the correlation between visceral fat thickness and presence of 
microalbuminuria in 50 type 2 diabetic individuals. Among the 50 patients it was 
found that 13 patients had microalbuminuria out of which more than 90% of the 
patients had a visceral fat thickness of more than 7. This clearly shows that there 
is a strong positive correlation between increased visceral fat and 
microalbuminuria.  
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TABLE XII 
COMPARISON BETWEEN BODY MASS INDEX AND 
MICROALBUMINURIA IN TYPE 2 DIABETIC SUBJECTS. 
 
 
 
 
Microalbuminuria vs BMI Mean SD p value 
Present  (13) 29.59 1.82 < 0.001 
Nil  (37) 26.92 1.19 
 
 
 
 
 As visceral fat and microalbuminuria was compared, this picture shows the 
comparison between BMI and microalbuminuria. 13 patients among 50 were 
found to have microalbuminuria, out of which most of the patients belong to the 
group of BMI > 28. The mean BMI
microalbuminuria was 29.59 . 
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TABLE XIII 
NUMBER OF PATIENTS IN DIFFERENT MEASUREMENTS OF 
VISCERAL FAT THICKNES 
 
Viseral Fat No.of cases 
< 5.5 17 
5.6 - 6.5 16 
6.6 - 7.5 13 
> 7.5 4 
total 50 
 
 
 
 
 This picture shows the number of cases with different visceral fat thickness 
measurements. Around 34% of patients had a visceral fat of < 5.5. Around 32% 
of patients had a visceral fat thickness between 5.6 
had visceral fat thickness of 6.6 
thickness of more than 7.5, who had high levels of TG
microalbuminuria too.  
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TABLE XIV 
COMPARISON OF OCCURRENCE OF INCREASED TGL IN 
DIFFERENT LEVELS OF VISCERAL FAT THICKNESS IN TYPE 2 
DIABETIC SUBJECTS 
 
 
 
 
Viseral Fat TGL Mean SD p' value 
< 5.5  (17) 147.8 34.9 
5.6 - 6.5  (16) 176.6 18.2 
> 6.5  (17) 210.4 41.8 < 0.001 
 This picture shows the triglyceride mean levels in different measurements of 
visceral fat thickness. Of the 50 subjects, 17 patients had a VFT of < 5.5 who had 
a TGL levels of around 147.8. But patients who had high visceral fat thickness of 
more than 6.5 significantly had high levels of triglycerides and their mean level 
was around 176.6. Therefore there is a strong positive correlation between 
increased visceral fat thickness and triglycerides levels. 
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TABLE XV 
COMPARISON BETWEEN MICROALBUMINURIA AND 
TRIGLYCERIDES LEVEL IN TYPE 2 DIABETIC SUBJECTS 
 
 
 
 
 
 
 
Microalbuminuria vs  TGL TGL  Mean SD p value 
Present  (13) 212.15 42.4 < 0.001 
Nil  (37) 166.41 35.02 
 This picture shows the comparison between presence of microalbuminuria and 
triglyceride levels in 50 subjects of type 2 diabetes mellitus. As already 
mentioned 13 patients had microalbuminuria. More than 90 % of these patients 
had a visceral fat thickness of more than 7.5. Similarly when their triglyceride 
levels were compared, the mean TGL level was around 212. Therefore there a 
strong positive correlation between increased visceral fat thickness with 
microalbuminuria and triglycerides levels. 
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TABLE XVI 
COMPARISON BETWEEN MICROALBUMINURIA AND LDL LEVELS 
IN TYPE 2 DIABETIC SUBJECTS 
 
 
 
 
 
 
 
Microalbuminuria vs  LDL LDL  Mean SD p value 
Present  (13) 178.8 22.74 < 0.001 
Nil  (37) 133.56 24.96 
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This picture shows the correlation between the presence of microalbuminuria and 
LDL levels. Out of the 13 patients who had microalbuminuria, the mean LDL 
levels was around 178.8. Therefore there is a positive correlation between 
increased visceral fat thickness with microalbuminuria and LDL levels.  
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DISCUSSION 
                            Diabetes mellitus refers to  a group of metabolic disorders and 
india is referred to the diabetic capital of the world. At the same time obesity is 
the emerging problem in most of the developing countries and also in developed 
countries. 
                           Previously many parameters were used to assess the 
cardiovascular risk of any individual. BMI, waist hip ratio etc were used 
previously. But now measuring the visceral adiposity is considered as the method 
of choice in assessing the risk for cardiovascular diseases. This visceral adiposity 
or visceral fat thickness can be measured by computerized tomography , dual 
energy X ray absorptiometry  etc.. 
                       Eventhough   measuring the VFT  by CT was considered the gold 
standard method, there are various study which has been conducted with 
measurement of visceral adiposity with ultrasonography , and it has been proved 
that , ultrasound measurement of visceral adiposity is equally efficacious when 
compared with CT. So, in our study also, ultrasound was used to measure the 
visceral adiposity .  
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                            Moreover, due to high cost and radiation exposure, CT  is not 
preferred. And since ultrasound is a non invasive , easily measurable and less 
costly, USG  is preferred over CT.  Another emerging method in measuring the 
visceral adiposity is measuring the sagittal abdominal diameter (SAG). 
                            Many studies have been done on sagittal abdominal diameter, 
and this will also show the cardiovascular risk of the patients. SAG  is measured 
by a separate caliper known as Sagittometer.   
                           But in our study, USG guided visceral adiposity measurement in 
type 2 diabetic subjects with BMI > 25 showed a strong positive correlation with 
TGL, LDL and microalbuminuria. The cut off for visceral fat thickness was kept 
in a range as less than 5.5, 5.6 to 6.5 , 6.6 to 7.5 and more than 7.5. patients were 
classified according to these categories and their lipid profile was compared.  
There was a clear positive correlation between increased visceral fat thickness 
and elevated LDL, TGL and microalbuminuria .  
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SUMMARY 
- Among the 50 diabetic subjects (25 males and 25 females) attending the 
department of Diabetology in Government Rajaji Hospital, Madurai, with  
BMI of > 25, increased visceral fat thickness was found in 12 males and 
15 females.  
- Among the 50 patients, all the patients who had increased visceral fat 
thickness had an increased triglyceride level and increased LDL level. 
Therefore there is a strong positive correlation between increased visceral 
fat thickness and LDL, TGL levels. 
- Similarly , 13 patients had microalbuminuria, out of which more than 90% 
of patients had a Visceral fat thickness of more than 7.5 . They also had a 
increased triglyceride level and LDL levels.  
- There was no significant correlation between visceral fat thickness and 
total cholesterol levels. Similarly even HDL  didn’t show show any strong 
correlation with visceral fat thickness levels.  
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CONCLUSION 
                       Eventhough there are many parameters to assess the cardiovascular 
risk like BMI, WHR, etc, measuring  the visceral fat thickness is a reliable 
indicator to assess the cardiovascular risk.  
                       This study which was conducted in Government Rajaji Hospital 
among 50 type 2 diabetic subjects, showed a strong positive correlation between 
visceral fat thickness with LDL and triglycerides levels. Similarly 13 patients had 
microalbuminuria whose visceral fat thickness was > 7.5.  
                     Because of presence of microalbuminuia, there is evidence of 
subclinical endothelial injury in this patients who are more prone for 
cardiovascular risk in later part of their life. These patients also had a elevated 
LDL and TGL which supports the point on cardiovascular risk.  
                         Eventhough CT was considered to be gold standard in measuring 
the visceral fat thickness, there are many studies which showed ultrasonographic 
measurement of visceral fat was equally efficient in assessing the cardiovascular 
risk. Moreover due to radiation exposure and cost of CT, this study was 
conducted with  ultrsonographic measurement alone.   
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PROFORMA 
 NAME :                                  AGE:                              SEX: 
I)GENERAL ASSESSMENT  
1) ANTHROPOMETRIC MEASUREMENTS  
Height (mts):                                      Weight (kgs) : 
BMI (kg/m2) :  
Waist (cms) :                                       Hip (cms) : 
WHR : 
2) BLOOD PRESSURE :             mmHg (supine position) 
3) SMOKIING : 
4) ALCOHOL: 
5) FAMILY HISTORY : 
          Diabetes -   
          Hypertension –  
          CAD –  
          Renal failure –  
6) TREATMENT HISTORY  
Diet : 
Oral hypoglycemic drugs / insulin :  
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II)BLOOD INVESTIGATIONS 
1) Fasting blood sugar:  
2) Post prandial blood sugar: 
3) Blood urea:  
4) Serum creatinine:  
5) Fasting lipid profile : 
III) URINE EXAMINATION 
1) Spot urine sample for microalbuminuria : 
IV) ULTRASOUND MEASUREMENT OF VFT  
1) Subcutaneous fat thickness :  
2) Visceral fat thickness : 
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ABBREVIATIONS 
DM – DIABETES MELLITUS 
BMI – BODY MASS INDEX 
WHR – WAIST HIP RATIO 
VFT – VISCERAL FAT THICKNESS 
SFT – SUBCUTANEOUS FAT THICKNESS 
VFA – VISCERAL FAT ADIPOSITY  
HbA1c – GLYCATED HEMOGLOBIN  
LDL – LOW DENSITY LIPOPROTEIN 
HDL – HIGH DENSITY LIPOPROTEIN 
VLDL – VERY LOW DENSITY LIPOPROTEIN  
TGL – TRIGLYCERIDES 
CT – COMPUTERISED TOMOGRAPHY 
USG – ULTRASONOGRAPHY. 
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